Impact of Nasopharyngeal FilmArray Respiratory Panel Results on Antimicrobial Decisions in Hospitalized Patients

Table 1

Demographics, MRSA NS, procalcitonin, and immunosuppression in groups A, B, and C.

	Group A				Group B				Group C
	+A	−A	Total	value	+B	−B	Total	value	+C	−C	Total	value
N	28	84	112		59	147	206		56	171	227
Age				0.11^1				0.36^1				0.61^1
Median	60.0	68.0	66.0		71.0	68.0	69.0		68.0	69.0	68.0
Gender				0.44^2				0.94^2				0.18^2
Female	17 (60.7%)	44 (52.4%)	61 (54.5%)		24 (40.7%)	59 (40.1%)	83 (40.3%)		33 (58.9%)	83 (48.5%)	116 (51.1%)
Male	11 (39.3%)	40 (47.6%)	51 (45.5%)		35 (59.3%)	88 (59.9%)	123 (59.7%)		23 (41.1%)	88 (51.5%)	111 (48.9%)
MRSA NS				0.43^3				0.34^3				0.67^3
Not done	26 (92.9%)	67 (79.8%)	93 (83.0%)		31 (52.5%)	69 (46.9%)	100 (48.5%)		35 (62.5%)	94 (55.0%)	129 (56.8%)
Negative	2 (7.1%)	16 (19.0%)	18 (16.1%)		26 (44.1%)	76 (51.7%)	102 (49.5%)		19 (33.9%)	68 (39.8%)	87 (38.3%)
Positive	0 (0.0%)	1 (1.2%)	1 (0.9%)		2 (3.4%)	2 (1.4%)	4 (1.9%)		2 (3.6%)	9 (5.3%)	11 (4.8%)
Procalcitonin				0.37^2				0.52^2				0.89^2
Not done	25 (89.3%)	69 (82.1%)	94 (83.9%)		48 (81.4%)	125 (85.0%)	173 (84.0%)		53 (94.6%)	161 (94.2%)	214 (94.3%)
Negative	3 (10.7%)	15 (17.9%)	18 (16.1%)		11 (18.6%)	22 (15.0%)	33 (16.0%)		3 (5.4%)	10 (5.8%)	13 (5.7%)
Immunosuppression				0.91^2				0.81^2				0.91^2
No	14 (50.0%)	41 (48.8%)	55 (49.1%)		29 (49.2%)	75 (51.0%)	104 (50.5%)		27 (48.2%)	84 (49.1%)	111 (48.9%)
Yes	14 (50.0%)	43 (51.2%)	57 (50.9%)		30 (50.8%)	72 (49.0%)	102 (49.5%)		29 (51.8%)	87 (50.9%)	116 (51.1%)

MRSA NS, methicillin-resistant Staphylococcus aureus nasal swab; ¹Wilcoxon; ²chi-square; ³Fisher’s exact.